

D Adam Lauver

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8498741/publications.pdf>

Version: 2024-02-01

21
papers

538
citations

932766

10
h-index

887659

17
g-index

21
all docs

21
docs citations

21
times ranked

937
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving corrected QT; Why individual correction is not enough. <i>Journal of Pharmacological and Toxicological Methods</i> , 2022, 113, 107126.	0.3	8
2	>Clopidogrel Rescues the Adverse Cerebral Vascular Effects Associated with Angiotensin II-Induced Hypertension. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
3	Pleiotropic effects of clopidogrel. <i>Purinergic Signalling</i> , 2022, 18, 253-265.	1.1	4
4	Endothelial P2Y ₂ -mediated vasoconstriction is inhibited in middle cerebral arteries of rabbits treated with clopidogrel. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
5	Which QT Correction Method is Most Consistent?. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
6	Clopidogrel treatment inhibits P2Y ₂ -Mediated constriction in the rabbit middle cerebral artery. <i>European Journal of Pharmacology</i> , 2021, 911, 174545.	1.7	2
7	Contemporary use of and outcomes associated with ultra-low contrast volume in patients undergoing percutaneous coronary interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 222-230.	0.7	38
8	Relationship of clinical adverse event reports to models of arrhythmia risk. <i>Journal of Pharmacological and Toxicological Methods</i> , 2019, 100, 106622.	0.3	2
9	DT-678 inhibits platelet activation with lower tendency for bleeding compared to existing P2Y ₁₂ antagonists. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00509.	1.1	4
10	Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 359, 11-17.	1.3	10
11	CYP-independent inhibition of platelet aggregation in rabbits by a mixed disulfide conjugate of clopidogrel. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1304-1311.	1.8	6
12	Sildenafil Citrate for Prophylaxis of Nephropathy in an Animal Model of Contrast-Induced Acute Kidney Injury. <i>PLoS ONE</i> , 2014, 9, e113598.	1.1	53
13	Formation, Reactivity, and Antiplatelet Activity of Mixed Disulfide Conjugates of Clopidogrel. <i>Molecular Pharmacology</i> , 2013, 83, 848-856.	1.0	14
14	Oral Pretreatment With Liposomal Glutathione Attenuates Reperfusion Injury in Rabbit Isolated Hearts. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 233-239.	0.8	12
15	Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 28-33.	3.3	159
16	Disodium Disuccinate Astaxanthin Prevents Carotid Artery Rethrombosis and ex vivo Platelet Activation. <i>Pharmacology</i> , 2008, 82, 67-73.	0.9	26
17	RO3244794, an IP receptor antagonist, shortens the time to occlusion in a canine model of coronary artery thrombosis. <i>FASEB Journal</i> , 2008, 22, 640-640.	0.2	0
18	Sulodexide: A Renewed Interest in This Glycosaminoglycan. <i>Cardiovascular Drug Reviews</i> , 2006, 24, 214-226.	4.4	65

#	ARTICLE	IF	CITATIONS
19	Sulodexide Attenuates Myocardial Ischemia/Reperfusion Injury and the Deposition of C-Reactive Protein in Areas of Infarction without Affecting Hemostasis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 794-800.	1.3	42
20	Disodium Disuccinate Astaxanthin (Cardax) Attenuates Complement Activation and Reduces Myocardial Injury following Ischemia/Reperfusion. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 686-692.	1.3	65
21	Comparative Analysis of Various Platelet Glycoprotein IIb/IIIa Antagonists on Shear-Induced Platelet Activation and Adhesion. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 303, 1114-1120.	1.3	28